Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated.

Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Far fewer babies had severe cases of the respiratory illness RSV, in a winter in which a new monoclonal and vaccine became ...

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

In a recent study of a population of infants, published online May 6 in Pediatrics, 72% of infants were found to be immunized ...

The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional ...

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. plans to require all new vaccines be tested against a placebo ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.